Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757183 | 0.85 | MEN1 (0.79) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL2794662 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL219432 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Fluoride SCHEMBL27959930 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| Piperazine SCHEMBL28229145 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL27485345 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1USP2CYP2C9 | |
| SCHEMBL4146271 | 0.81 | SLC6A9 (0.59) | MEN1KMT2AMGLLCYP2D6SLC6A9 | |
| SCHEMBL27770322 | 0.81 | SLC6A9 (0.59) | MEN1KMT2AMGLLCYP2D6SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| CN-101479243-B | Glycine transporter-1 inhibitors | AMGEN INC | 2013-01-02 | — | — | CN | disclosed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8183244-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | disclosed |
| CN-101479243-A | Glycine transporter-1 inhibitors | AMGEN INC (US) | 2009-07-08 | — | — | CN | disclosed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | MEN1 2632/4885KMT2A 947/4885OPRD1 2031/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.